newsfilter
← Latest News
Business Wire·

Humanigen Reports Second Quarter 2021 Financial Results

Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called "cytokine storm'" with its lead drug candidate, lenzilumab, today provided a corporate and regulat